Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL4903 Autologous T-Cell Injection for Relapsed/Refractory Multiple Myeloma
NCT07234721Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label trial of SL4903 in multiple myeloma (MM) (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Number and incidence rate of adverse events at 1 month. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
SL4903
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07234721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234721.